FDA Proposes Priorities For Cosmetic Ingredient Review: Mica, Probiotics, CBD
Executive Summary
Nakissa Sadrieh, director of cosmetics at FDA and the agency’s CIR liaison, floated the three potential review priorities at the CIR Expert Panel’s April 8-9 meeting in Washington. It’s the most for-cause targets proposed by the agency in recent memory, and CIR leadership noted that they pose considerable challenges.
You may also be interested in...
Dutch Biotech Touts Enzyme-Powered Eczema Cream As ‘Smarter And Safer’ Solution
Headquartered in The Hague, Netherlands, Micreos is focused on developing targeted antibacterial products to replace antibiotics, protect against food contamination and treat inflammatory skin conditions. The firm’s Gladskin Eczema Cream, now available stateside, uses a patented enzyme technology to destroy Staphylococcus aureus bacteria while leaving skin’s beneficial flora intact.
Bayer Harnessing Skin Microbiome In New Product Development
Bayer has teamed up with skin microbiome specialist Azitra to develop consumer health products for a host of conditions.
Cosmetics Market In 2019: CBD, Microplastic And US Sunscreen Uncertainty Among Year’s Biggest Issues
The opportunity represented by cannabidiol, and the uncertain future for commonly used sunscreen active ingredients in the US and microplastic in the EU, were issues of high interest among cosmetics industry stakeholders in 2019.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to HBW Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
